Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2017 August;108(4) > Minerva Medica 2017 August;108(4):384-6

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878


eTOC

 

LETTERS TO THE EDITOR  


Minerva Medica 2017 August;108(4):384-6

DOI: 10.23736/S0026-4806.17.05048-0

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes

Manuel GONZÁLEZ-ORTIZ , Fernando GROVER-PÁEZ, Cristal DÍAZ-CRUZ, Anayeli de J. PATIÑO-LAGUNA, Luis D. LÓPEZ-MURILLO, Esperanza MARTÍNEZ-ABUNDIS

Department of Physiology, Institute of Experimental and Clinical Therapeutics, Health Science University Center, University of Guadalajara, Guadalajara, Mexico


PDF  


top of page

Publication History

Issue published online: June 28, 2017
Manuscript accepted: February 14, 2017
Manuscript revised: February 7, 2017
Manuscript received: January 25, 2017

Cite this article as

González-Ortiz M, Grover-Páez F, Díaz-Cruz C, de J. Patiño-Laguna A, López-Murillo LD, Martínez-Abundis E. Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes. Minerva Med 2017;108:384-6. DOI:10.23736/S0026-4806.17.05048-0

Corresponding author e-mail

uiec@prodigy.net.mx